Article Information
History
- January 6, 2022.
Article Versions
- You are currently viewing Version 1 of this article (January 6, 2022 - 10:13).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Amanda Zheutlin, PhD1,*,
- Miles Ott, PhD1,*,
- Ran Sun, PhD1,
- Natalia Zemlianskaia, PhD1,
- Meagan Rubel, PhD1,
- Jennifer Hayden, MPH1,
- Breno Neri, PhD1,
- Tripthi Kamath, PhD1,
- Najat Khan, PhD1,
- Sebastian Schneeweiss, MD, ScD2,3 and
- Khaled Sarsour, PhD1,#
- 1Data Science, Research & Development, Janssen Pharmaceuticals
- 2Department of Science, Aetion Inc., New York, NY
- 3Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- ↵#Contact information for corresponding author
Khaled Sarsour, PhD, 260 E Grand Ave., South San Francisco, CA 94080, ksarsour{at}its.jnj.com
↵* Authors contributed equally
Posted January 06, 2022.
Durability of Protection against COVID-19 Breakthrough Infections and Severe Disease by Vaccines in the United States
